Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medical Facilities Corp T.DR

Alternate Symbol(s):  MFCSF

Medical Facilities Corporation is a Canada-based company, which owns a portfolio of surgical facilities in the United States. The Company owns interest in four specialty surgical hospitals (SSHs) located in Arkansas, Oklahoma, and South Dakota, and one ambulatory surgery centers (ASC) located in California. ASCs are specialized surgical centers that only provide outpatient procedures, whereas SSHs are licensed for both inpatient and outpatient surgeries. The SSHs and ASC provide facilities, including staffing, surgical materials and supplies, and other support necessary for scheduled surgical, pain management, imaging, and diagnostic procedures and derive their revenue primarily from the fees charged for the use of these facilities. In addition, two of the SSHs provide urgent care services. The facilities focus on a limited number of clinical specialties such as orthopedics, neurosurgery, pain management and other non-emergency elective procedures.


TSX:DR - Post by User

Bullboard Posts
Post by felix10on Aug 09, 2018 4:01pm
182 Views
Post# 28435882

TD maintains Buy rating and $16.50 Price Target

TD maintains Buy rating and $16.50 Price Target
Event
 
MFC's Q2/18 results and commentary were highlighted by strong
performances at Sioux Falls (SFSH) and Black Hills (BHSH), with an offsetting
drag from the Unity Medical (UMASH) and Arkansas (ASH) facilities. In addition,
the newly acquired Nueterra ASCs contributed ~$9.6mm to quarterly revenues.
 
Q2/18 revenue grew 10.8% y/y to $106.5mm vs. the TD estimate of $104mm.
Corporate EBITDA of $23.9mm compares to the TD estimate of $24.7mm. The
Q2/18 payout ratio was 74.3%. As of June 30, 2018, MFC had $37.2mm in cash and
$167.9mm in debt, with net debt/EBITDA of ~1.3x.
 
Impact: MIXED
 
Positives
The Dakotas Look Strong — SFSH and BHSH revenues grew 5% and 7.4%
y/y, driven by case volume and favourable case mix. These are MFC's largest
facilities contributing 48% of overall revenues. Recent performance appears to
counter competition concerns in their respective markets.
 
Nueterra's Arrival - Nueterra contributed ~$9.6mm in revenues in its first full
quarter under the MFC banner. In the medium term, we expect Nueterra to
deliver ASC management expertise, cost efficiencies, and business development
leverage. Nueterra will also contribute critical diversification - raising MFC's ASC
exposure to 11% of revenues and broadening its base by six states.
Constraints
 
UMASH Turns Profitable but Remains on the Watchlist — UMASH's operating
income turned marginally profitable in Q2/18. Management continues to focus on
physician recruitment at the facility and we anticipate improvement in H2/18. Key
challenges include capacity underutilization and high revenue concentration.
 
TD Investment Conclusion
 
We are maintaining our BUY rating and C$16.50 target price. MFC continues to
leverage its competitive positioning and secular fundamentals to capitalize on highmargin
procedures. Despite quarterly lumpiness, MFC's annual revenue showed
consistent growth. MFC's return to our $16.50 target price has narrowed on today's
trading activity. We are nonetheless maintaining our BUY rating in anticipation of the
stock settling to more sustainable levels in the immediate term.
Bullboard Posts